AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Feb 2023 03:00 PM
RNS
Total Voting Rights
26 Jan 2023 06:15 PM
RNS
Update on Evusheld US EUA
16 Jan 2023 07:00 AM
RNS
Acquisition of Neogene Therapeutics completed
11 Jan 2023 01:00 PM
RNS
Airsupra (PT027) approved in US for asthma
09 Jan 2023 07:00 AM
RNS
AstraZeneca acquire CinCor for cardiorenal asset
03 Jan 2023 03:00 PM
RNS
Total Voting Rights
30 Dec 2022 11:00 AM
RNS
Director/PDMR Shareholding
28 Dec 2022 07:05 AM
RNS
Calquence Japan approval for treatment-naïve CLL
28 Dec 2022 07:00 AM
RNS
Imfinzi, Imjudo approved in Japan for 3 cancers
21 Dec 2022 07:05 AM
RNS
Lynparza approved in EU for prostate cancer
21 Dec 2022 07:00 AM
RNS
Imfinzi approved in EU for biliary tract cancer
19 Dec 2022 07:20 AM
RNS
Enhertu recommended for EU approval in HER2-low BC
19 Dec 2022 07:15 AM
RNS
Enhertu approved in EU for gastric cancer
19 Dec 2022 07:10 AM
RNS
Imfinzi + Imjudo recommended for approvals in EU
19 Dec 2022 07:05 AM
RNS
Update on Imfinzi PEARL trial
19 Dec 2022 07:00 AM
RNS
Forxiga CHMP opinion for symptomatic chronic HF
15 Dec 2022 07:00 AM
RNS
Update on US review of Lynparza PROpel sNDA
08 Dec 2022 01:30 PM
RNS
Capivasertib PFS in HR-positive breast cancer
01 Dec 2022 03:00 PM
RNS
Block listing Interim Review
01 Dec 2022 03:00 PM
RNS
Total Voting Rights
30 Nov 2022 07:05 AM
RNS
AstraZeneca announces sale of West Chester site
29 Nov 2022 07:00 AM
RNS
AstraZeneca to acquire Neogene Therapeutics
23 Nov 2022 03:30 PM
RNS
Director/PDMR Shareholding
14 Nov 2022 07:10 AM
RNS
Enhertu recommended for EU approval in gastric
14 Nov 2022 07:05 AM
RNS
Imfinzi recommended for approval in the EU for BTC
14 Nov 2022 07:00 AM
RNS
Lynparza combo recommended in the EU for mCRPC
11 Nov 2022 07:00 AM
RNS
Imfinzi + Imjudo approved in US for lung cancer
10 Nov 2022 07:00 AM
RNS
YTD and Q3 2022 Results
09 Nov 2022 07:00 AM
RNS
FDA Advisory Committee recommends PT027 in asthma
04 Nov 2022 07:00 AM
RNS
Beyfortus (nirsevimab) approved in EU
01 Nov 2022 03:00 PM
RNS
Total Voting Rights
26 Oct 2022 07:00 AM
RNS
Capivasertib Phase III trial met primary endpoints
25 Oct 2022 07:00 AM
RNS
Update on MESSINA Phase III trial
24 Oct 2022 07:00 AM
RNS
Imfinzi + Imjudo approved in advanced liver cancer
03 Oct 2022 03:00 PM
RNS
Total Voting Rights
30 Sep 2022 10:30 AM
RNS
Board Committee Changes
27 Sep 2022 07:05 AM
RNS
Koselugo approved in Japan for NF1
27 Sep 2022 07:00 AM
RNS
Tezspire approved in Japan for severe asthma
23 Sep 2022 07:00 AM
RNS
Ultomiris approved in EU for gMG
22 Sep 2022 07:00 AM
RNS
Lynparza approved in China for ovarian cancer
21 Sep 2022 07:00 AM
RNS
Tezspire approved in the EU for severe asthma
20 Sep 2022 07:00 AM
RNS
Evusheld approved in EU for COVID-19 treatment
16 Sep 2022 07:10 AM
RNS
Danicopan Phase III trial met primary endpoint
16 Sep 2022 07:05 AM
RNS
Evusheld positive CHMP opinion in EU
16 Sep 2022 07:00 AM
RNS
Nirsevimab recommended for approval in EU by CHMP
05 Sep 2022 07:05 AM
RNS
Forxiga approved in China for CKD
05 Sep 2022 07:00 AM
RNS
Imfinzi approved in US for biliary tract cancer
01 Sep 2022 03:00 PM
RNS
Total Voting Rights
30 Aug 2022 01:00 PM
RNS
Evusheld approved for COVID-19 in Japan
30 Aug 2022 07:01 AM
RNS
Farxiga shows CV mortality benefit across EF range
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings